CANVAS - CANagliflozin cardioVascular Assessment Study
Status:
Completed
Trial end date:
2017-02-22
Target enrollment:
Participant gender:
Summary
The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2
diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac
events (MACE). Other objectives include evaluating the overall safety, tolerability, and
effectiveness of canagliflozin.
The data from this study will be combined with the data from CANVAS-R study (Study of the
Effects of Canagliflozin on Renal Endpoints in Adult Subjects with T2DM, NCT01989754) in a
pre-specified integrated analysis of CV safety outcomes to satisfy US FDA post-marketing
requirements for canagliflozin.